GlassScriptPhysician profile
Akintomide Apara
NPI 1356720395
$4,075.80
in general payments reported to CMS, 2019-2025
20 companies · $929 in 2025
The $929 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.48 · 2022: $671 · 2023: $1,370 · 2024: $1,065 · 2025: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,310 · Travel and Lodging: $54.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,309.58 |
| Travel and Lodging | $54.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,245.79 | 2022-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $534.19 | 2022-2025 | Vabysmo |
| Astellas Pharma US INC | $367.84 | 2023-2025 | Izervay |
| Abbvie INC. | $355.58 | 2023-2025 | Ozurdex |
| Apellis Pharmaceuticals, INC. | $321.46 | 2023-2025 | Syfovre |
| Sight Sciences, INC. | $233.60 | 2022 | |
| Alcon Vision LLC | $201.63 | 2019-2024 | Rocklatan |
| Regeneron Pharmaceuticals, INC. | $182.67 | 2023 | Eylea |
| Eyepoint US, INC. | $137.51 | 2023 | |
| Harrow Eye, LLC | $112.41 | 2024-2025 | Triesence, Vevye, Iheezo |
| Mallinckrodt Hospital Products INC. | $107.40 | 2025 | Acthar |
| Bausch & Lomb Americas INC. | $70.86 | 2023-2025 | Vyzulta, Scoutpro Osmolarity System |
| Amgen INC. | $36.82 | 2025 | Tepezza |
| Thea Pharma INC. | $35.49 | 2024 | Iyuzeh |
| Sandoz INC. | $27.76 | 2024 | Cimerli |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $26.95 | 2024 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $21.91 | 2022 | |
| Neurotech Pharmaceuticals, INC. | $21.57 | 2025 | |
| Horizon Therapeutics Plc | $20.29 | 2022 | |
| Oyster Point Pharma, INC. | $14.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akintomide Apara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.